Related Experiment Video
Updated: Mar 13, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of
Giandomenico Roviello1, Maria Rosa Cappelletti, Laura Zanotti
1Section of Pharmacology and University Center DIFF-Drug Innovation Forward Future, Department of Molecular and Translational Medicine, University of Brescia, Brescia U.S. Terapia Molecolare e Farmacogenomica Radiotherapy Department, ASST Cremona, Cremona Section of Experimental Oncology, Department of Clinical and Experimental Medicine, University of Parma, Parma Unit of General Medicine, Azienda Ospedaliera "C. Poma" Presidio Ospedaliero di Pieve di Coriano, Mantova Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Background:
The novel hormonal drugs have recently entered in the armamentarium of therapies for treatment of metastatic castration-resistant prostate cancer (CRPC). First reports are available for their use in elderly men with CRPC.
Method:
A meta-analysis of randomized controlled trials (RCTs) has been performed. PubMed, the Cochrane Library, and American Society of Clinical Oncology (ASCO) University Meeting were searched for data on the use of new hormonal treatment in elderly patients with CRPC.
Results:
Nine studies for a total of 3512 elderly patients were available for meta-analysis. Six studies reported outcomes of patients aged >75 years old while 2 studies reported on patients aged >70 years old. The pooled analysis of the androgen synthesis inhibitors revealed significantly increased overall survival (OS) due to antiandrogen agents compared with placebo or placebo and prednisone (hazard ratio (HR) for death: HR = 0.74, 95% CI: 0.67-0.82; P < 0.00001). Moreover, the new antiandrogenic therapy significantly improved the progression-free survival (HR = 0.45, 95% CI: 0.31-0.65; P < 0.0001). The incidence of any grade ≥3 adverse effect was only moderately higher during with the antiandrogenic therapy as compared to the control arms (response rate = 1.03, 95% CI: 0.88-1.20; P = 0.72).
Conclusion:
This study confirmed that agents targeting the androgen axis (i.e., enzalutamide, abiraterone) significantly prolonged OS in elderly men with CRPC.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Drug Dosing: Geriatric Patients
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacodynamics in Geriatric Patients: Effects of Age
Menopause

